nach oben

Erschienen in:

01.05.2007 | Original Article

Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles

verfasst von: Takafumi Minami, Satoko Matsueda, Hiroko Takedatsu, Masahiro Tanaka, Masanori Noguchi, Hirotsugu Uemura, Kyogo Itoh, Mamoru Harada

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 5/2007

Einloggen, um Zugang zu erhalten

Abstract

SART3-derived peptides applicable to prostate cancer patients with HLA-A3 supertype alleles were identified in order to expand the possibility of an anti-cancer vaccine, because the peptide vaccine candidates receiving the most attention thus far have been the HLA-A2 and HLA-A24 alleles. Twenty-nine SART3-derived peptides that were prepared based on the binding motif to the HLA-A3 supertype alleles (HLA-A11, -A31, and -A33) were first screened for their recognizability by immunoglobulin G (IgG) of prostate cancer patients and subsequently for the potential to induce peptide-specific cytotoxic T lymphocytes (CTLs) from HLA-A3 supertype⁺ prostate cancer patients. As a result, five SART3 peptides were frequently recognized by IgG, and two of them—SART3 _511-19 and SART3 _734-42—efficiently induced peptide-specific and cancer-reactive CTLs. Their cytotoxicity toward prostate cancer cells was ascribed to peptide-specific and CD8⁺ T cells. These results indicate that these two SART3 peptides could be promising candidates for peptide-based immunotherapy for HLA-A3 supertype⁺ prostate cancer patients.

Aizawa M (1986) The Proceedings of the 3rd Asia-Oceania histocompatibility workshop conference. Oxford University Press; Oxford, pp 1090-103

Greenlee RT, Murray T, Bolden S, Wingo PA (2000) Cancer statistics, 2000. CA Cancer J Clin 50:7–33CrossRefPubMed

Hida N, Maeda Y, Katagiri K, Takasu H, Harada M, Itoh K (2002) A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulation. Cancer Immunol Immunother 51:219–228CrossRefPubMed

Imanishi T, Akazawa T, Kimura A (1992) Allele and haplotype frequencies for HLA and complement loci in various ethnic groups. In: Tsuji K, Aizawa M, Sasazuki T (eds) HLA 1991,vol. 1. Oxford Scientific Publications, Oxford, pp 1065-220

Kawagoe N, Shintaku I, Yutani S, Etoh H, Matuoka K, Noda S, Itoh K (2000) Expression of the SART3 tumor rejection antigen in renal cell carcinoma. J Urol 164:2090–2095CrossRefPubMed

Komatsu N, Shichijo S, Nakagawa M, Itoh K (2004) New multiplexed flow cytometoric assay to measure anti-peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization. Scand J Clin Invest 64:1–11CrossRef

Matsueda S, Takedatsu H, Yao A, Tanaka M, Noguchi M, Itoh K, Harada M (2005) Identification of peptide vaccine candidates for prostate cancer patients with HLA-A3 supertype alleles. Clin Cancer Res 11:6933–6943CrossRefPubMed

Mine T, Gouhara R, Hida N, Imai N, Azuma K, Rikimaru T, Katagiri K, Nishikori M, Sukehiro A, Nakagawa M, Yamada A, Aizawa H, Shirouzu K, Itoh K, Yamana H (2003) Immunological evaluation of CTL precursor-oriented vaccines for advanced lung cancer patients. Cancer Sci 94:548–556CrossRefPubMed

Mine T, Sato Y, Noguchi M, Sasatomi T, Gouhara R, Tsuda N, Tanaka S, Shomura H, Katagiri K, Rikimaru T, Shichijo S, Kamura T, Hashimoto T, Shirouzu K, Yamada A, Todo S, Itoh K, Yamana H (2004) Humoral responses to peptides correlated with overall survival in advanced cancer patients vaccinated with peptides based on pre-existing, peptide-specific cellular responses. Clin Cancer Res 10:929–937CrossRefPubMed

10.

Murayama K, Kobayashi T, Imaizumi T, Matsunaga K, Kuramoto T, Shigemori M, Shichijo S, Itoh K (2000) Expression of the SART3 tumor-rejection antigen in brain tumors and induction of cytotoxic T lymphocytes by its peptides. J Immunother 23:511–518CrossRefPubMed

11.

Nakatsura T, Senju S, Ito M, Nishimura Y, Itoh K (2002) Cellular and humoral immune responses to a human pancreatic cancer antigen, coactosin-like protein, originally defined by the SEREX method. Eur J Immunol 32:826–836CrossRefPubMed

12.

Niiya F, Nishizaka S, Matsunaga K, Koufuji K, Mori M, Katai H, Yamana H, Itoh K (2000) Expression of SART3 tumor-rejection antigen in gastric cancers. Jpn J Cancer Res 91:337–342PubMed

13.

Noguchi M, Kobayashi K, Suetsugu N, Tomiyasu K, Suekane S, Yamada A, Itoh K, Noda S (2003) Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination. Prostate 57:80–92CrossRefPubMed

14.

Ogata R, Matsueda S, Yao A, Noguchi M, Itoh K, Harada M (2004) Identification of polycomb group protein enhancer of zeste homolog 2 (EZH2)-derived peptides immunogenic in HLA-A24⁺ prostate cancer patients. Prostate 60:273–281CrossRefPubMed

15.

Ohkouchi S, Yamada A, Imai N, Mine t, Harada K, Shichijo S, Maeda Y, Saijo Y, Nukiwa T, Itoh K (2002) Non-mutated tumor-rejection antigen peptides elicit type-I allergy in the majority of healthy individuals. Tissue Antigens 59:259–272CrossRefPubMed

16.

Parker KC, Bednarek MA, Coligan JE (1994) Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 152:163–175PubMed

17.

Rammensee HG, Friege T, Stevanovics S (1995) MHC ligands and peptides motifs. Immunogenetics 41:178–228CrossRefPubMed

18.

Renkvist N, Castelli C, Robbins PF, Parmiani G (2001) A listing of human tumor antigens recognized by T cells. Cancer Immunol Immunother 50:3–15CrossRefPubMed

19.

Sato Y, Shomura H, Maeda Y, Mine T, Ueno Y, Akasaka Y, Kondo M, Takahashi S, Shinohara T, Katagiri K, Sato M, Okada S, Matsui K, Yamada A, Yamana H, Itoh K, Todo S (2003) Immunogical evaluation of peptide vaccination for patients with gasctirc cancer based on pre-existing cellular response to peptide. Cancer Sci 94:802–808CrossRefPubMed

20.

Sette A, Sidney J (1999) Nine major HLA classI supertypes account for the vast preponderance of HLA-A and –B polymorphism. Immunogenetics 50:201–212CrossRefPubMed

21.

Sidney J, Grey HM, Southwood S, Celis E, Wentworth PA, del Guercio MF, Kubo RT, Chestnut RW, Sette A (1996) Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. Hum Immunol 45:79–93CrossRefPubMed

22.

Takedatsu H, Shichijo S, Katagiri K, Sawamizu H, Sata M, Itoh K (2004) Identification of peptide vaccine candidates sharing among HLA-A3⁺, -A11⁺, -A31⁺, and -A33⁺ cancer patients. Clin Cancer Res 10:1112–1120CrossRefPubMed

23.

Tatedatsu H, Yoshimoto K, Yakushiji K, Harada M, Shichijo S, Yamada A, Okamura T, Yamana H, Sata M, Itoh K (2004) Expression of epithelial cancer-related antigens in hematologic malignancies applicable for peptide-based immunotherapy. J Immunother 27:289–297CrossRef

24.

Tanaka S, Tsuda N, Kawano K, Sakamoto M, Nishida T, Hashimoto T, Shichijo S, Kamura T, Itoh K (2000) Expression of tumor-rejection antigens in gynecologic cancers. Jpn J Cancer Res 91:1177–1184PubMed

25.

Tsuda N, Murayama K, Ishida H, Matsunaga K, Komiya S, Itoh K, Yamada A (2001) Expression of a newly defined tumor-rejection antigen SART3 in musculoskeletal tumors and induction of HLA class I-restricted cytotoxic T lymphocytes by SART3-derived peptides. J Orthop Res 19:346–351CrossRefPubMed

26.

Wang RF, Johnston SL, Southwood S, Sette A, Rosenberg SA (1998) Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and –A33. J Immunol 160:890–897PubMed

27.

Yang D, Nakao M, Shichijo S, Sasatomi T, Takasu H, Matsumoto H, Mori K, Hayanshi A, Yamana H, Shirouzu K, Itoh K (1999) Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients. Cancer Res 59:4056–4063PubMed

28.

Yao A, Harada M, Matsueda S, Ishihara Y, Shoumura H, Takao Y, Noguchi M, Matsuoka K, Hara I, Kamidono S, Itoh K (2005) New epitope peptides derived from parathyroid hormone-related protein which have the capacity to induce prostate cancer-reactive cytotoxic T lymphocytes in HLA-A2⁺ prostate cancer patients. Prostate 62:233–242CrossRefPubMed

Titel: Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles
verfasst von: Takafumi Minami
Satoko Matsueda
Hiroko Takedatsu
Masahiro Tanaka
Masanori Noguchi
Hirotsugu Uemura
Kyogo Itoh
Mamoru Harada
Publikationsdatum: 01.05.2007
Verlag: Springer-Verlag
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 5/2007
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-006-0216-9

Springer Medizin

Identification of SART3-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from prostate cancer patients with HLA-A3 supertype alleles

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2007

Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients

Acknowledgement

HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination

Phase II study of interleukin-2 and 13-cis-retinoic acid as maintenance therapy in metastatic colorectal cancer

Activation of complement C3, C5, and C9 genes in tumors treated by photodynamic therapy

Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Update Onkologie